Abstract: The present application describes to the synthesis, formulation and uses of crosslinkable entities and crosslinked materials.

Abstract: Disclosed herein are methods, systems, and devices for oral drug delivery. The method generally involves orally administering a drug delivery device to the subject in need of treatment and triggering iontophoresis. The drug delivery device includes one or more active agents for delivery to the subject. The method can include the step of delivering the active agent to the intestinal mucosa after iontophoresis is triggered at the site, or simultaneously as iontophoresis is applied at the site. After the active agent(s) are delivered, the drug delivery device can be released from the intestinal mucosa. The iontophoresis can be performed for a period of time and at an electrical current that is effective to improve permeability of the one or more active agents across the intestine compared to orally administering the same drug delivery device in the absence of iontophoresis.

Abstract: The technology described herein is directed to ionic liquids and methods of drug delivery.

Abstract: Provided herein are polymeric particles and compositions (i.e., “backpacks”) that can adhere to cells and provide delivery of payload agents to those cells, and/or direct therapeutic activity of those cells.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.

Abstract: The technology described herein is directed to ionic liquids and methods of drug delivery.

Abstract: This document relates to methods and materials for tissue ablation. For example, methods for using a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) for tissue ablation are provided. In some cases, a composition including one or more ionic liquids (e.g., a composition including a LATTE solution) can be used to ablate tumor tissue within a mammal having cancer (e.g., to treat the mammal).

Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.

Abstract: The technology described herein is directed to ionic liquids for using the treatment or prevention of fungal infections.

Abstract: The technology described herein is directed to ionic liquids for using the treatment or prevention of fungal infections.

Abstract: Described herein are functionalizing nanocomplexes comprising one or more polyphenol molecules; and one or more biomolecules. Further described herein are functionalized cells comprising one or more of the nanocomplexes. In some embodiments, the biomolecules can be therapeutic agents and the functionalized cells can be administered to patients to provide improved delivery (e.g., dosing and specificity) of the therapeutic agent.

Abstract: The present application describes to the synthesis, formulation and uses of crosslinkable entities and crosslinked materials.

Abstract: The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

Abstract: Described herein are compositions comprising polymers conjugated to at least one immunomodulator, e.g., a) a retinoid and an imidazoquinoline, b) a retinoid and a HDAC inhibitor, or c) a HDAC inhibitor and an imidazoquinoline. Further described herein are methods of using said compositions, e.g., in modulating immune responses and/or treating a disease such as cancer.

Abstract: The technology described herein is directed to adjuvants comprising ionic liquids, as well as compositions and methods utilizing or comprising such adjuvants.

Abstract: The technology described herein is directed to in vitro methods of identifying or selecting combinations of therapeutic agents that are effective in vivo. These methods provide improved methods of treatment, e.g., treatment of cancer. Further, provided herein are novel combinations of anti-cancer agents which are demonstrated to have surprising efficacy.

Abstract: The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

Abstract: Provided herein are erythrocytes with polymeric particles (i.e., ‘backpacks’) adhered that provide delivery of payload therapeutic agents to subjects administered these cells.

Abstract: The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.